"Polyhedrocytes are likely to be central to preventing bleeding and promoting blood flow after damage to blood vessels has begun to heal. However, when the process goes awry, in the case of clotting diseases, these tightly packed erythrocytes present a challenge to clot-busting thrombolytic agents, as they are more resistant to fibrinolysis," said co-author John W. Weisel, Ph.D., Professor of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania.
"This landmark publication demonstrates that T2HemoStat can be an important tool to identify biomarkers for companion diagnostics or new drug development, in this case, specifically targeted at highly contracted clots containing polyhedrocytes," added Tom Lowery, Ph.D., Chief Scientific Officer, T2 Biosystems and co-author in the study. "Furthermore, this new finding enabled by T2HemoStat demonstrates the power and versatility of our T2MR technology both in the research setting and as it can relate to meaningful clinical advances."
The paper, entitled "Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin", was authored by Douglas B. Cines, Tatiana Lebedeva, Chandrasekaran Nagaswami, Vincent Hayes, Walter Massefski, Rustem I. Litvinov, Lubica Rauova, Thomas J. Lowery and John W. Weisel. After identification of samples and sample conditions that form this novel clot with T2MR, the group used scanning electron and optical microscopy to determine that contracted clots consist of a meshwork of fibrin and platelet aggregates on the exterior of the clot with a closely-packed, tessellated array of compressed polyhedral erythrocytes (polyhedrocytes) on the interior.
This phenomenon was observable both in vivo and in vitro in humans and mice, and is likely caused by the force that the fibrin and platelets place upon the erythrocytes, as centrifugation of erythrocytes in the
|Contact: Kari Watson|
MacDougall Biomedical Communications, Inc.